A phase II study of a human anti-PDGFR alpha monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors

Wagner, A.J.; Kindler, H.; Gelderblom, H.; Schoffski, P.; Bauer, S.; Hohenberger, P.; ... ; Rutkowski, P. (2017)

Article / Letter to editor

• gastrointestinal stromal tumor
• platelet-derived growth factor receptor alpha
• IMC-3G3
• mutation
• monoclonal antibody

• All authors: Wagner, A.J.; Kindler, H.; Gelderblom, H.; Schoffski, P.; Bauer, S.; Hohenberger, P.; Kopp, H.G.; Lopez-Martin, J.A.; Peeters, M.; Reichardt, P.; Qin, A.; Nippgen, J.; Ilaria, R.L.; Rutkowski, P.
• Date: 2017-03-31
• Journal: Annals of Oncology
• Volume: 28
• Issue: 3
• Pages: 541 - 546
• DOI: doi:10.1093/annonc/mdw659